×

Sign In

Search
Home

Novo Nordisk secures license to weight-loss drug candidate from China’s United Labs

By Thomson Reuters Mar 24, 2025 | 5:21 AM

(Reuters) -China-based United Laboratories International said on Monday it will license its weight-loss drug candidate to Danish drugmaker Novo Nordisk in a deal worth up to $2 billion.

(Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli)

Wall Street CEOs see some tariff impact filtering into customer behavior

Pipeline operator Kinder Morgan posts higher second-quarter profit

United Airlines sees profit below estimates as travel spending dips

Fed's Bostic: Recent data show price pressures may be building

Trump thinks China will begin sentencing people to death for fentanyl distribution

US transfers acreage near proposed mining road to Alaska native group

Privacy Policy
Terms Of Service

Copyright © 2025. All Rights Reserved.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

For the health and safety of everyone, our offices are temporarily closed to the public. If you have won a prize from us we will be mailing it to you or will contact you with specific information needed to redeem your prize. Feel free to call us with questions during weekday business hours at 715-842-1672.